Skip to main content
. 2014 Jun 11;34(24):8175–8185. doi: 10.1523/JNEUROSCI.1137-14.2014

Figure 2.

Figure 2.

Deletion of astroglial CCL2 diminishes EAE clinical severity. A, Clinical scores were recorded daily post-MOG peptide immunization through day 85. n = 12 for control; n = 16 for mGFAPCre/CCL2flx/flx/RosaEYFP mice. *p = 0.137 (day 10), 0.0480 (day 12), 0.0116 (day 14), and 0.0427 (day 15) (Mann–Whitney test). B, Mean cumulative clinical scores from A. *p = 0.0351 (unpaired t test). C, Table summarizing EAE clinical parameters in mGFAPCre/RosaEYFP and mGFAPCre/CCL2flx/flx/RosaEYFP mice. Data are mean ± SEM for at least five independent experiments.